Santhera enters license agreement with Chiesi Group; Tonix's cocaine intoxication drug, Iovance's cervical cancer treatment win FDA's breakthrough status
→ Swiss-based Santhera has entered an exclusive global — except for the US and Canada— license agreement with international research-focused healthcare group Chiesi Farmaceutici. The company says that Chiesi Group will in-license Raxone for the treatment of LHON for a total consideration of CHF 105 million (about $104 million), and this will constitute an upfront of about $49.5 million and near-to mid-term sales milestone payments of up to about $54.5 million. Following the completion of “certain reimbursement and post-regulatory commitments on the part of Santhera,” Chiesi Group will have the option to fully acquire Santhera’s Raxone business.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.